Showing results for "hiroaki eshima"
Showing 1 - 2 of 2 Results
Adult content is visible.
2024
EN
Skeletal Muscle Health in Metabolic Diseases explores the vital role of skeletal muscle in regulating energy metabolism and its interactions with other organs, such as the liver and brain, in the context of metabolic diseases like obesity, diabetes, and fatty liver disease. This comprehensive guide covers how metabolic disorders impact muscle glucose metabolism, liver function, and brain health, alongside the effects of nutrition and exercise on carbohydrate metabolism. Readers will gain i...
2024
EN
Skeletal Muscle Health in Metabolic Diseases explores the vital role of skeletal muscle in regulating energy metabolism and its interactions with other organs, such as the liver and brain, in the context of metabolic diseases like obesity, diabetes, and fatty liver disease. This comprehensive guide covers how metabolic disorders impact muscle glucose metabolism, liver function, and brain health, alongside the effects of nutrition and exercise on carbohydrate metabolism. Readers will gain i...
People who read this also enjoyed
- Series -
- Oxford Diabetes Library
2012
EN
Around 250 million people currently suffer from diabetes globally and this number is expected to reach 370 million people within the next 20 years. Fortunately in recent years our understanding of the pathogenesis and management of Type 2 diabetes has increased enormously. Innovative new drugs have been developed and the evidence base for treating diabetes and preventing its complications is now outstanding. This second edition has been fully updated throughout to include all of the latest...
2015
EN
The International Textbook of Diabetes Mellitus has been a successful, well-respected medical textbook for almost 20 years, over 3 editions. Encyclopaedic and international in scope, the textbook covers all aspects of diabetes ensuring a truly multidisciplinary and global approach. Sections covered include epidemiology, diagnosis, pathogenesis, management and complications of diabetes and public health issues worldwide. It incorporates a vast amount of new data regarding the scien...
- Book Volume 39-3 -
- The Clinics: Internal Medicine
2010
EN
This issue of Endocrinology and Metabolism Clinics of North America provides the endocrinologist with essential updates on treatment of type 1 diabetes, with an eye toward future trends and developments. The Guest Editors brought together a remarkable group of notable authors, such as Paul Robertson, President of the National Diabetes Association. Topics covered include epidemiology; economics; contemporary management; inpatient management; update on insulin pumps and continuous glucose mo...
Metabolic Syndrome
Underlying Mechanisms and Drug Therapies
2011
EN
METABOLIC SYNDROMEA comprehensive look at the fight against the metabolic syndrome epidemicIncreasing risk of cardiovascular disease and diabetes, the metabolic syndrome is a world health problem that demands attention from all levels of the health care industry. Metabolic Syndrome: Underlying Mechanisms and Drug therapies extensively covers the metabolic syndrome with an emphasis on drug discovery efforts, providing a context of m...
Ketogenic Diet and Metabolic Therapies
Expanded Roles in Health and Disease
2016
EN
Ketogenic diets have been used to successfully treat epilepsy and stop seizures for nearly a century. When more traditional therapies, such as pharmacology, reach their limitations for treatment, the metabolic approach surpasses, targeting the overall physiology and homeostatic functions of the patient. Ketogenic Diet and Metabolic Therapies is the first comprehensive scientific resource on the ketogenic diet, covering the latest research including the biomedical mechanisms, established an...
2012
EN
Diabetes mellitus affects approximately 20 million people in the US, or nearly 7% of the population. It is expected to increase by 70% within the next 25 years, and numerous epidemiologic studies have demonstrated that type 2 diabetes increases the risk of cardiovascular morbidity and mortality. It is estimated to cost over $92 billion in health care costs and lost productivity. The increased risk is due to the detrimental vascular effects of prolonged exposure to a hyperglycemic, oxidant-...
Aging
Oxidative Stress and Dietary Antioxidants
2014
EN
Aging: Oxidative Stress and Dietary Antioxidants bridges the trans-disciplinary divide and covers in a single volume the science of oxidative stress in aging and the potentially therapeutic use of natural antioxidants in the diet or food matrix. The processes within the science of oxidative stress are described in concert with other processes, such as apoptosis, cell signaling, and receptor mediated responses. This approach recognizes that diseases are often multifactorial, and oxidative s...
2018
EN
An ideal reference for practitioners and health care professionals who care for patients with abnormal lipids, Dyslipidemia: A Clinical Approach provides clinically relevant, user-friendly information on all aspects of this rapidly evolving field. In addition to concise yet in-depth coverage of key topics, chapters include background information, evidence from the literature, and author commentary on conflicting or debated recommendations. Written by respected leaders in cardiology, nutrit...
2013
EN
Metabolic Syndrome and Neurological Disorders brings together information on the cluster of common pathologies which cause metabolic syndrome - abdominal obesity linked to an excess of visceral fat, insulin resistance, dyslipidemia and hypertension - to provide a comprehensive and cutting edge exploration of the link between metabolic syndrome and neurological disorders.Metabolic syndrome is recognized to play a role in neurological disorders such as stroke, Alzheimer's di...
2013
EN
New Mechanisms in Glucose Control presents a clear overview of the new drugs and treatment therapies that have been developed in recent years to help improve glycaemic management for the diabetic patient, namely the incretin mimetics (GLP-1 agonists) and DPP-4 inhibitors. It also considers other drug classes currently in development and undergoing clinical trials including the SGLT2 inhibitors and other pipeline products. In addition to pharma cotherapeutic agents, the rol...











